Over the last decade, the European medical cannabis landscape has seen a significant surge of new products entering the market, providing patients, especially in the UK and Germany, with a greater variety than ever before.
Prohibition Partners will soon be launching the 10th addition of their industry leading European Cannabis Report, marking the milestone with a ground-up overhaul of its tried and trusted format.
The UK is the primary driver of new growth in Europe’s medical cannabis market, with sales of medical cannabis greater than expected due to ‘unusually high’ consumption volumes on a per-patient basis.
The UK’s medical cannabis market is set to become the second largest in Europe this year, as has long been predicted by analysts.
GERMANY is continuing to see cannabis companies from across the globe pile into its medical cannabis market in the hopes of securing their piece of the pie.
NEW sales forecasts for the medical cannabis market in Europe predict that €353 million-worth of medical cannabis will be sold on the continent in 2022, rising to €2.3 billion by 2026 – a potential 544% increase over the forecast period.
